Leerink Highlights 3 Biotechs that could benefit from the ASH conference

On Monday, Leerink issued a report previewing the American Society of Hematology annual meeting which will be held from December 5th to December 8th. Leerink believes that this meeting will have meaningful clinical updates for Alnylam Pharmaceuticals Inc.

, Juno Therapeutics

, and Karyopharm Therapeutics Inc.

. Leerink reiterated their OP rating for ALNY, JUNO, and KPTI. Michael Schmidt and Jonathan Chang, analysts at Leerink, highlighted each company in their report. Alnylam: "ALNY will present important updates from ALN-CC5 (complement-mediated diseases) and ALN-AT3 (bleeding disorders) Phase I trials, respectively, including multi-dose cohorts, which should further validate early clinical results presented from either agent this summer." Juno: "Six ASH presentations for JUNO will include updates from JCAR014 (anti-CD19, FHCRC) trials in NHL, chronic lymphocytic leukemia (CLL)... We'd expect updates at ASH to include more pts and data on durability in NHL, which could help position JUNO's product vs. competitors." Karyopharm: "Clinical data presentations on selinexor combinations include (1) a summary of Ph II dose finding trials showing that a flat dose of 60mg selinexor twice weekly provides the best risk-benefit profile." Overall the analysts believe that this presentation will contain meaningful data that could serve as catalysts for these companies going forward, particularly as it relates to Phase 1 and Phase 2 data. Positive data may validate early clinical results leading to positive investor sentiment. Currently Alnylam Pharmaceuticals is trading at $105.37, down 1.87 percent. Currently Juno Therapeutics is trading at $55.83, down 0.89 percent. Currently Karyopharm Therapeutics is trading at $18.38, down 3.16 percent.